Serum insulin-like growth factor-I (IGF-I) levels during long-term IGF- I treatment of children and adults with primary GH resistance (Laron syndrome)

Journal of Pediatric Endocrinology and Metabolism

Volumn 12, Issue 2, 1999, Pages 145-152

  Laron, Zvi ^a   Klinger, B ^b   Silbergeld, A ^b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b NONE

Author keywords

GH resistance (insensitivity); IGF I treatment; IGFBP 3; Laron syndrome; Serum IGF I

Indexed keywords

FK 780; GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; DOSE RESPONSE; DRUG MONITORING; FEMALE; HORMONE BLOOD LEVEL; HORMONE RESISTANCE; HUMAN; INFANT; LARON SYNDROME; LONG TERM CARE; MALE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032936909     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.1999.12.2.145     Document Type: Article

References (40)

1. Keret R, Pertzelan A, Zeharia A, Zadik A, Laron Z. Growth hormone (hGH) secretion and turnover in three patients with Laron-type dwarfism. Isr J Med Sci 1988; 34: 75-79.
2. Laron Z, Blum W, Chatelain P, Ranke M, Rosenfeld R, Savage M, Underwood L. Classification of growth hormone insensitivity syndrome. J Pediatr 1993; 122: 241.
3. Laron Z, Pertzelan A, Karp M, Kowadlo-Silbergeld A, Daughaday WH. Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone. Measurement of sulfation factor, metabolic and linear growth responses. J Clin Endocrinol Metab 1971; 33: 332-342.
4. Laron Z. Prismatic cases: Laron syndrome (primary growth hormone resistance). From patient to laboratory to patient. J Clin Endocrinol Metab 1995; 80: 1526-1573.
5. Godowski PJ, Leung DW, Meacham LR, Galgani JP, Hellmiss R, Keret R, Rotwein PS, Parks JS, Laron Z, Wood WI. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in 2 patients with Laron type dwarfism. Proc Natl Acad Sci USA 1989; 86: 8083-8087.
6. Amselem S, Sobrier ML, Dastot F, Duquesnoy O, Duriez B, Goossens M. Molecular basis of inherent growth hormone resistance in childhood. Baillière's Clin Endocrinol Metab 1996; 10: 353-369.
7. Laron Z, Klinger B, Eshet R, Kanety H, Karasik A, Silbergeld A. Laron syndrome due to a post-receptor defect: response to IGF-I treatment. Isr J Med Sci 1993; 29: 757-763.
8. Woods KA, Camacho-Hubner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996; 335:1363-1367.
9. Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab 1995; 8: 149-158.
10. Ranke MB, Savage MO, Chatelain PG, Preece MA, Blum WF, Wilton P, for the Pharmacia Study Group on Insulin-like Growth Factor I. Treatment in growth hormone insensitivity syndromes: insulin-like growth factor I improves height in growth hormone insensitivity: Two years' results. Horm Res 1995; 44: 253-264.
11. Backeljauw PF, Underwood LE, the GHIS Collaborative Group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - a Clinical Research Center study. J Clin Endocrinol Metab 1996; 81: 3312-3317.
12. Laron Z, Klinger B, Silbergeld A, Lewin B, Erster B, Gil-Ad I. Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH. Acta Endocrinol 1990; 123: 378-382.
13. Klinger B, Garty M, Silbergeld A, Laron Z. Elimination characteristics of intravenously administered rIGF-I in Laron type dwarfs (LTD). Develop Pharmacol Therap 1990; 15: 196-199.
14. Niwa M, Sato Y, Saito Y, Uchiyama F, Ono H, Yamashita M, Kitaguchi T, Shiga Y, Notani J, Yamada H, Ishii Y, Ueda I, Takagi Y. Chemical synthesis, cloning and expression of genes for human somatomedin C (insulin like growth factor I) and 59Val somatomedin C. Ann NY Acad Sci 1986; 469: 31-52.
15. Silbergeld A, Litwin A, Bruchis S, Varsano I, Laron Z. Insulin-like growth factor I (IGF-I) in healthy children adolescents and adults as determined by a radioimmunaassay specific for the synthetic 53-70 peptide region. Clin Endocrinol 1986; 25: 67-74.
16. Klinger B, Anin S, Silbergeld A, Eshet R, Laron Z. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Clin Endocrinol 1998; 48: 81-87.
17. Laron Z, Anin S, Klipper-Aubach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference and body fat in patients with Laron-type dwarfism. Lancet 1992; 339: 1258-1261.
18. Klinger B, Laron Z. Renal function in Laron syndrome patients treated by insulin-like growth factor-I. Pediatr Nephrol 1994; 8: 684-688.
19. Laron Z, Klinger B. IGF-I treatment of adult patients with Laron syndrome. Clin Endocrinol 1994; 41: 631-638.
20. Laron Z, Avitzur Y, Klinger B. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. Metabolism 1995; 44: 113-118.
21. Laron Z, Avitzur Y, Klinger B. Insulin resistance in Laron syndrome (primary insulin-like growth factor-I [IGF-I] deficiency) and effect of IGF-I replacement therapy. J Pediatr Endocrinol Metab 1997; 10 (Suppl 1): 105-115.
22. Klinger B, Jensen LT, Silbergeld A, Laron Z. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome. Clin Endocrinol 1996; 45: 423-429.
23. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DEL. Insulin-like growth factor-I decreases serum lipoprotein(a) during long-term treatment of patients with Laron syndrome. Metabolism 1996; 45: 1263-1266.
24. Laron Z, Wang XL, Silbergeld A, Wilcken DEL. Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a). Eur J Endocrinol 1997; 136: 377-381
25. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular biology of IGF-I receptor. In: Merimee T. Laron Z. eds. Growth Hormone, IGF-I and Growth: New Views of Old Concepts. Modern Endocrinology and Diabetes, Vol. 4. Tel Aviv-London: Freund Publ House Ltd., 1996; 73-99.
26. Zapf J, Gosteli-Peter M, Schmid C. Insulin-like growth factor binding proteins (IGFBPs). In: Merimee T, Laron Z, eds. Growth Hormone, IGF-I and Growth: New Views of Old Concepts. Modern Endocrinology and Diabetes, Vol. 4. Tel Aviv-London: Freund Publ House Ltd., 1996; 45-71.
27. Laron Z, Klinger B, Blum WF, Silbergeld A, Ranke MB. IGF binding protein 3 in patients with LTD: effect of exogenous rIGF-I. Clin Endocrinol 1992; 36: 301-304.
28. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld, RG. Two year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor-I in 22 children: comparison of two dosage levels and to GH treated GH deficiency. J Clin Endocrinol Metab 1997; 82: 629-633.
29. Laron Z, Klinger B. Effect of insulin like growth factor -I treatment on serum androgens, testicular and penile size in males with Laron syndrome (primary growth hormone resistance). Eur J Endocrinol 1998; 138: 176-180.
30. Cotterill AM, Holly JM, Taylor AM, Davies SC, Coulson VJ, Preece MA, Wass JAH, Savage MO. The insulin-like growth factor (IGF)-binding proteins and IGF bioactivity in Laron-type dwarfism. J Clin Endocrinol Metab 1992; 74: 56-63.
31. Rosenbloom AL, Guevara-Aguirre J, Fielder PJ, Gargosky S, Rosenfeld RG, Berg MA, Francke U, Diamond FB Jr, Vaccarello MA. Laron syndrome (growth hormone receptor deficiency) in Ecuador: Clinical and biochemical characteristics. In: Laron Z, Parks JS, eds. Lessons from Laron Syndrome (LS) 1966-1992. A Model of GH and IGF-I Action and Interaction. Basel: S. Karger, Pediatr Adolesc Endocrinol 1993; 24: 34-52.
32. Kanety H, Karasik A, Klinger B, Silbergeld A, Laron Z. Long-term treatment of Laron type dwarfs with insulin-like growth factor I increases serum insulin-like growth factor-binding protein 3 in the absence of growth hormone activity. Acta Endocrinol 1993; 128: 144-149.
33. Kanety H, Silbergeld A, Klinger B, Karasik A, Baxter RC, Laron Z. Long term effects of insulin-like growth factor-I (IGF-I) on serum IGF-I, IGF-binding protein-3 (IGFBP3) and acid labile subunit in Laron syndrome patients with normal GHBP. Eur J Endocrinol 1997; 137: 626-630.
34. Zapf J, Haun M, Waldvogel M, Futo E, Hasler H, Binz K, Guler HP, Schmid C, Froesch ER. Recombinant human insulin-like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats. Proc Natl Acad Sci USA 1989; 86: 3813-3817.
35. Thissen JP, Underwood LE, Maiter D, Maes M, Clemmons DR, Ketelslegers JM. Failure of insulin-like growth factor-I (IGF-I) infusion to promote growth in protein-restricted rats despite normalization of serum IGF-I concentrations. Endocrinology 1991; 128: 885-890.
36. Scharf J, Ramadori G, Braulke T, Hartmann H, Synthesis of insulin-like growth factor binding proteins and of the acid-labile subunit in primary cultures of rat hepatocytes, of Kupffer cells, and in cocultures: regulation by insulin, insulin-like growth factor and growth hormone. Hepatology 1996; 23: 818-827.
37. Uchijima Y, Takenaka A, Takahashi S, Noguchi T. Production of insulin-like growth factors and their binding proteins in primary cultures of rat liver parenchymal and nonparenchymal cells. Biosci Biotechnol Biochem 1995; 59: 1503-1515.
38. Giannini S, Cresci B, Manuell C, Fujita-Yamaguchi Y, Romagnani P, Mohan S, Rotella CM. Insulin-like growth factor binding protein production in bovine retinal endothelial cells. Metabolism 1997; 46: 1367-1379.
39. Laron Z, Suikkari AM, Klinger B, Silbergeld A, Pertzelan A, Seppala M, Koivisto VA. Growth hormone and insulin-like growth factor regulate insulin-like growth factor binding protein in Laron type dwarfism, growth hormone deficiency and constitutional growth retardation. Acta Endocrinol 1992; 127: 351-358.
40. Laron Z. Recombinant somatomedin-1 (insulin-like growth factor-I). Clinical pharmacology and potential treatment of endocrine and metabolic disorders. Biodrugs 1999; 11: 55-70.